[Whole abdominal irradiation of ovarian cancer in combined treatment with OK-432 picibanil].
One hundred seventeen patients with postoperative ovarian cancer who were treated with whole abdominal irradiation by the open-field technique were analyzed as to the effectiveness of combined therapy with or without OK-432. OK-432, 0.2 to 2.0 (KE) (kev) daily, has been used to prevent bone marrow suppression since 1978 at NIRS. Cumulative five-year survival rates were 63.6% in the OK-432 group (37 patients) and 54.5% in the NON-OK-432 group (34 patients). The complete rates of previously arranged treatment schedules were 81% and 66% in the two groups, respectively, as we originally intended.
D000005:Abdomen / Q000528:radiation effects*; D002288:Adenocarcinoma, Mucinous / Q000532:radiotherapy / Q000628:therapy*; D001688:Biological Products / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003536:Cystadenocarcinoma / Q000532:radiotherapy / Q000628:therapy*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000532:radiotherapy / Q000628:therapy*; D010844:Picibanil / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy
D001688:Biological Products; D010844:Picibanil